Advances in biochemical engineering/biotechnology最新文献

Industrially applied bioprocesses for the reduction of C1 gases (CO₂ and/or CO) are based in particular on (syn)gas fermentation with acetogenic bacteria and on photobioprocesses with microalgae. In each case, process engineering characteristics of the autotrophic microorganisms are specified and process engineering aspects for improving gas and electron supply are summarized before suitable bioreactor configurations are discussed for the production of organic products under given economic constraints. Additionally, requirements for the purity of C1 gases are summarized briefly. Finally, similarities and differences in microbial CO₂ valorization are depicted comparing gas fermentations with acetogenic bacteria and photobioprocesses with microalgae.

The interaction of the human user with equipment and software is a central aspect of the work in the life science laboratory. The enhancement of the usability and intuition of software and hardware products, as well as holistic interaction solutions are a demand from all stakeholders in the scientific laboratory who desire more efficient workflows. Shorter training periods, parallelization of workflows, improved data integrity, and enhanced safety are only a few advantages innovative intuitive human-device-interfaces can bring. With recent advances in artificial intelligence (AI), the availability of smart devices, as well as unified communication protocols, holistic interaction solutions are on the rise. Future interaction in the laboratory will not be limited to pushing mechanical buttons on equipment. Instead, the interplay between voice, gestures, and innovative hard- and software components will drive interactions in the laboratory into a more streamlined future.

Limitations of the current tools used in the drug development process, cell cultures, and animal models have highlighted the need for a new powerful tool that can emulate the human physiology in vitro. Advances in the field of microfluidics have made the realization of this tool closer than ever. Organ-on-a-chip platforms have been the first step forward, leading to the combination and integration of multiple organ models in the same platform with human-on-a-chip being the ultimate goal. Despite the current progress and technological developments, there are still several unmet engineering and biological challenges curtailing their development and widespread application in the biomedical field. The potentials, challenges, and current work on this unprecedented tool are being discussed in this chapter.

Syngas, a gaseous mixture of CO, H₂ and CO₂, can be produced by gasification of carbon-containing materials, including organic waste materials or lignocellulosic biomass. The conversion of bio-based syngas to chemicals is foreseen as an important process in circular bioeconomy. Carbon monoxide is also produced as a waste gas in many industrial sectors (e.g., chemical, energy, steel). Often, the purity level of bio-based syngas and waste gases is low and/or the ratios of syngas components are not adequate for chemical conversion (e.g., by Fischer-Tropsch). Microbes are robust catalysts to transform impure syngas into a broad spectrum of products. Fermentation of CO-rich waste gases to ethanol has reached commercial scale (by axenic cultures of Clostridium species), but production of other chemical building blocks is underexplored. Currently, genetic engineering of carboxydotrophic acetogens is applied to increase the portfolio of products from syngas/CO, but the limited energy metabolism of these microbes limits product yields and applications (for example, only products requiring low levels of ATP for synthesis can be produced). An alternative approach is to explore microbial consortia, including open mixed cultures and synthetic co-cultures, to create a metabolic network based on CO conversion that can yield products such as medium-chain carboxylic acids, higher alcohols and other added-value chemicals.

In this chapter the concept of research data management is highlighted in the context of the data publication and data infrastructures. One focus of this contribution lies on the topics of metadata and the FAIR data principles associated with data sharing and data infrastructures such as data repositories. The challenges for researchers and research communities towards open science are discussed and the first steps towards FAIR data infrastructures are illustrated.

In recent years, 3D printing has had a huge impact on the field of biotechnology: from 3D-printed pharmaceuticals to tissue engineering and microfluidic chips. Microfluidic chips are of particular interest and importance for the field of biotechnology, since they allow for the analysis and screening of a wide range of biomolecules - including single cells, proteins, and DNA. The fabrication of microfluidic chips has historically been time-consuming, however, and is typically limited to 2.5 dimensional structures and a restricted palette of well-known materials. Due to the high surface-to-volume ratios in microfluidic chips, the nature of the chip material is of paramount importance to the final system behavior. With the emergence of 3D printing, however, a wide range of microfluidic systems are now being printed for the first time in a manner that facilitates flexibility while minimizing time and cost. Nevertheless, resolution and material choices still remain challenges and in the focus of current research, aiming for (1) 3D printing with high resolutions in the range of tens of micrometers and (2) a wider range of available materials for these high-resolution prints. The first part of this chapter highlights recent emerging technologies in the field of high-resolution printing via stereolithography (SL) and 2-photon polymerization (2PP) and seeks to identify particularly interesting emerging technologies which could have a major impact on the field in the near future. The second part of this chapter highlights current developments in the field of materials that are used for these high-resolution 3D printing technologies.

In a similar vein to Industry 4.0 in manufacturing industries, digitisation is making inroads in the laboratory industry in the form of Laboratory 4.0, or networked laboratories. Companies can gain decisive competitive edges by automating their work processes and systems and networking them with each other and primary IT systems. A uniform communication standard such as OPC UA, a well-established global standard in the aforementioned manufacturing industries, is essential to a modular, scalable network of heterogeneous laboratory structures. Can the laboratory industry benefit from this standard and the years of development experience? In SPECTARIS, the German Industry Association for Optics, Photonics, Analytical and Medical Technologies, over 30 global market leaders, hidden champions and drivers of innovation in the laboratory industry put their heads together in the "Networked Laboratory Devices" working group and created the "Laboratory and Analytical Device Standard", or LADS for short. Unlike numerous other attempts to establish communication standards for laboratories, LADS is based on the advanced OPC UA standard and takes an agnostic approach to cover the variety of devices, systems and requirements in laboratories. In this context, "agnostic" refers to the generic design and display of potentially as-yet-unknown aspects of the flow of information or communication structures. For the first time, LADS allows for modular, scalable networking of heterogeneous laboratory structures, efficient data transfers and - currently unused - user, process and device-based data analysis (keywords: big data, predictive analytics, data science) - even taking normative requirements into consideration. This agnostic modelling makes LADS a future-proof communication solution for the laboratory industry, the likes of which the world has never seen.

The isolation and screening of bacteria and fungi for the production of surface-active compounds has been the basis for the majority of the biosurfactants discovered to date. Hence, a wide variety of well-established and relatively simple methods are available for screening, mostly focused on the detection of surface or interfacial activity of the culture supernatant. However, the success of any biodiscovery effort, specifically aiming to access novelty, relies directly on the characteristics being screened for and the uniqueness of the microorganisms being screened. Therefore, given that rather few novel biosurfactant structures have been discovered during the last decade, advanced strategies are now needed to widen access to novel chemistries and properties. In addition, more modern Omics technologies should be considered to the traditional culture-based approaches for biosurfactant discovery. This chapter summarizes the screening methods and strategies typically used for the discovery of biosurfactants and highlights some of the Omics-based approaches that have resulted in the discovery of unique biosurfactants. These studies illustrate the potentially enormous diversity that has yet to be unlocked and how we can begin to tap into these biological resources.

The implementation of continuous-flow transformations in biocatalysis has received remarkable attention in the last few years. Flow microfluidic reactors represent a crucial technological tool that has catalyzed this trend by promising tremendous improvement in biocatalytic processes across a host of different levels, including bioprocess development, intensification of reactions, implementation of new methods of reaction screening, and enhanced reaction scale-up. However, the full realization of this promise requires a synergy between these biocatalytic reaction features and the design and operation of microfluidic reactors. Here an overview on the different applications of flow biocatalysis is provided according to the format of the enzyme used: free vs immobilized form. Until now, flow biocatalysis has been implemented on a case-by-case approach but challenges and limitations are discussed in order to be overcome, and making continuous-flow microfluidic reactors as universal tool a reality.

Typical product development in biotechnological laboratories is a distributed and versatile process. Today's biotechnological laboratory devices are usually equipped with multiple sensors and a variety of interfaces. The existing software for biotechnological research and development is often specialized on specific tasks and thus generates task-specific information. Scientific personnel is confronted with an abundance of information from a variety of sources. Hence a comprehensive software backbone that structures the developmental process and maintains data from various sources is missing. Thus, it is not possible to maintain data access, documentation, reporting, availability, and proper data exchange. This chapter envisions a comprehensive digital infrastructure handling the data throughout an enzymatic product development process in a laboratory. The platform integrates a variety of software products, databases, and devices to make all product development life cycle (PDLC) data available and accessible to the scientific staff.